TW202346339A - 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案 - Google Patents

藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案 Download PDF

Info

Publication number
TW202346339A
TW202346339A TW112112351A TW112112351A TW202346339A TW 202346339 A TW202346339 A TW 202346339A TW 112112351 A TW112112351 A TW 112112351A TW 112112351 A TW112112351 A TW 112112351A TW 202346339 A TW202346339 A TW 202346339A
Authority
TW
Taiwan
Prior art keywords
antibody
ivig
individual
dose
crovacumab
Prior art date
Application number
TW112112351A
Other languages
English (en)
Chinese (zh)
Inventor
賽門 伯崔恩德 瑪麗 波爾托爾斯
五反田圭介
四宮賢治
亞歷山卓 安東尼 伯納德 莎斯泰利
安東尼 保羅 馬克森斯 蘇伯列特
Original Assignee
瑞士商赫孚孟拉羅股份公司
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司, 日商中外製藥股份有限公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202346339A publication Critical patent/TW202346339A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW112112351A 2022-04-04 2023-03-30 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案 TW202346339A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
EP22166586.2 2022-04-04

Publications (1)

Publication Number Publication Date
TW202346339A true TW202346339A (zh) 2023-12-01

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112351A TW202346339A (zh) 2022-04-04 2023-03-30 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
MX2024009673A (es) 2024-09-11
JP2025510490A (ja) 2025-04-15
AU2023248634A1 (en) 2024-05-16
CA3251879A1 (en) 2023-10-12
US20250236661A1 (en) 2025-07-24
EP4504773A1 (en) 2025-02-12
IL313962A (en) 2024-08-01
KR20240168923A (ko) 2024-12-02
WO2023194271A1 (en) 2023-10-12
CN118556078A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
JP6560808B2 (ja) 抗（＋）メタンフェタミンモノクローナル抗体
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
CN112203724A (zh) 使用利格珠单抗治疗慢性自发性荨麻疹的方法
KR20230027264A (ko) 통증의 치료에 사용하기 위한 tgf-알파 및 에피레귤린에 결합하는 항체
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
JP2024525870A (ja) 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療
TW202346339A (zh) 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案
TW202404632A (zh) 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案
TW202337913A (zh) 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
CN119789866A (zh) 用于治疗肌萎缩侧索硬化的药物制剂和给药方案
CN109641053A (zh) 给药方案
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
TW202345897A (zh) 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
TW202345896A (zh) 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
WO2025096435A1 (en) Treatment of complement-associated renal diseases
TW202500585A (zh) 每兩個月投予一次fviii模擬雙特異性抗體之方法
CN120265311A (zh) 免疫性血小板减少症的治疗
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗